Health · Pharma & Biotech · 2 days ago
Cheap product sold as Mounjaro raises safety concerns
A headline describes people buying a product because it was offered for half the price of Mounjaro.
After opening it, they found what the headline calls a dangerous identity.
The product is referred to as “India-zaro,” but its exact nature is not explained.
The headline does not say who bought it or where the purchase happened.
It also does not identify the danger or say whether anyone was harmed.
No further details or next steps are provided.
A product sold as Mounjaro at half the price was found to have a different identity when opened, Chosun Ilbo reported.
The headline describes that identity as “Indojaro.”
The article’s headline raises safety concerns about the product.
Chosun Ilbo published the report on October 10, 2026.
- Who
- A buyer, whose identity is not stated.
- What
- A product bought at half the price of Mounjaro was found to have a different identity when opened.
- When
- October 10, 2026, the report’s publication date; when the product was bought is not stated.
- Where
- Not stated.
- Why
- The report raises safety concerns about the product’s identity.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Reported product
- Indojaro
- Price comparison
- Half the price of Mounjaro
- Publication date
- October 10, 2026
- Outlet
- Chosun Ilbo
What people are saying
I bought it because it was half the price of Mounjaro
Sources
Related news
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Brazil suspends Peptistrong supplement and orders all batches recalled
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
